2018
Authors: Chiappini E, Galli L, Lisi C, et al.
Published in: J Acquir Immune Defic Syndr. 2018;79(1):54-61.
Background Strategies for prevention of HIV-1 mother-to-child transmission (PMTCT) have been continuously optimized. However, cases of vertical transmission continue to occur in high-income countries.
Objectives To investigate changes in PMTCT strategies adopted by Italian clinicians over time and to evaluate risk factors for transmission.
2018
Authors: Mallewa J, Szubert AJ, Mugyenyi P, et al.
Published in: Lancet HIV. 2018;5(5):e231-e240
Background In sub-Saharan Africa, severely immunocompromised HIV-infected individuals have a high risk of mortality during the first few months after starting antiretroviral therapy (ART). We hypothesise that universally providing ready-to-use supplementary food (RUSF) would increase early weight gain, thereby reducing early mortality compared with current guidelines recommending ready-to-use therapeutic food (RUTF) for severely malnourished individuals only.
2018
Authors: Kityo C, Szubert AJ, Siika A, et al.
Published in: PLoS Med. 2018; 15(12):e1002706
Background In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk of morbidity and mortality associated with immune reconstitution inflammatory syndrome (IRIS),
2018
Authors: Post FA, Szubert AJ, Prendergast AJ, et al; for Reduction of early mortality in HIV-infected adults and children starting an antiretroviral therapy (REALITY) trial team
Published in: Clin Infect Dis. 2018;66(2):S132-S139
Background In sub-Saharan Africa, 20%-25% of people starting antiretroviral therapy (ART) have severe immunosuppression; approximately 10% die within 3 months. In the Reduction of EArly mortaLITY (REALITY) randomized trial,
2018
Authors: Siika A, McCabe L, Bwakura-Dangarembizi M, et al; for REALITY Trial Team
Published in: Clin Infect Dis. 2018;66(2):S140-S146
Background Severely immunocompromised human immunodeficiency virus (HIV)–infected individuals have high mortality shortly after starting antiretroviral therapy (ART). We investigated predictors of early mortality and “late presenter” phenotypes.
Methods The Reduction of EArly MortaLITY (REALITY) trial enrolled ART-naive adults and children ≥5 years of age with CD4 counts <100 cells/μL initiating ART in Uganda,
2018
Authors: Favarato G, Bailey H, Burns F, et al.
Published in: Eur J Public Health. 2018;28(1):55-60
2018
Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord.
Published in: Clin Infect Dis. 2018;66(4):594-603.
Background Global data on durability of first-line antiretroviral therapy (ART) in children with HIV is limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand.
Methods Children <18-years initiating combination ART (≥2 nucleoside reverse transcriptase inhibitor (NRTI) plus non-NRTI (NNRTI) or boosted-protease inhibitor (PI)) were included.
2018
Authors: Zangari P, Palma P, Cotugno N, et al.
Published in: J Virus Erad.2018;4: 51–54
Abstract: The first EPIICAL General Assembly meeting was held in an atmosphere of growing optimism. Many novel and exciting proposals for HIV research studies were discussed and are described above. The consortium aims to maintain this integrated developmental research on NDMTs,
2017
Authors: Rinaldi S, Cotugno N, Pallikkuth S, Palma P, Pahwa S; on behalf of the EPIICAL Consortium
Published: 8th Conference on HIV Persistence
Background Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children provides an opportunity to limit the size of reservoir, but whether and how the time of ART treatment initiation can durably impact host immune responses associated with HIV infection is still unknown.
2017
Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.
Published in: Eur J Clin Pharmacol. 2017;73(4):463-468
Background Zidovudine (ZDV) has been associated with risk of haematological toxicity. Safety data from clinical trials is generally limited to 48 weeks. We assessed the short- and mid-term toxicity of ZDV/lamivudine (3TC) fixed-dose combination scored tablets in HIV-infected children followed in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) network.
2017
Authors: Bernays S, Paparini S, Seeley J, Namukwaya Kihika S, Gibb D, Rhodes T.
Published in: BMJ Open. 2017;7(2):e012934
Objectives A qualitative study of the BREATHER (PENTA 16) randomised clinical trial, which compared virological control of Short Cycle Therapy (SCT) (5 days on: 2 days off) with continuous efavirenz (EFV)-based antiretroviral therapy (CT) in children and young people (aged 8–24) living with HIV with viral load <50 c/mL to examine adaptation,
2017
Authors: Namukwaya S, Paparini S, Seeley J, Bernays S.
Published in: Front Public Health. 2017;5:343.
Abstract: Despite great advances in pediatric HIV care, rates and the extent of full disclosure of HIV status to infected children remain low especially in resource-constrained setting. The World Health Organisation recommends that, by the age of 10-12 years old,
2017
Authors: Hakim J, Musiime V, Szubert AJ; REALITY Trial Team
Published in: N Engl J Med. 2017;377(3):233-245
Background In sub-Saharan Africa, among patients with advanced human immunodeficiency virus (HIV) infection, the rate of death from infection (including tuberculosis and cryptococcus) shortly after the initiation of antiretroviral therapy (ART) is approximately 10%.
Methods In this factorial open-label trial conducted in Uganda,
2017
Authors: Schalkwijk S, Colbers A, Konopnicki D, et al.
Published in: Clin Infect Dis. 2017; 65(8):1335-1341.
2017
Authors: Judd A, Lodwick R, Noguera-Julian A, et al.. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
Published in: HIV Med. 2017;18(3):171-180
Objectives The aim of the study was to determine the time to, and risk factors for,
2017
Authors: Palma P, Chan M, Goodall R, Judd A, Gibb D, Babiker A, Rojo P.
Published: 35th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), May 23rd-27th May, 2017, Madrid
Background A major obstacle to curing HIV infection is persistence of virus as integrated proviral DNA in long-lived cells even after many years on ART.
2017
Authors: Palma P, Zangari P, Cotugno N, Rocca S, Nastouli E, McCoy LE, Ferns RB, Pahwa S, Rossi P
Published: 24th Conference on Retroviruses and Opportunistic Infections, February 13th – 16th, 2017, Seattle. P_1975.
Background It is still unknown whether the paucity of HIV-specific immune responses in early-treated (treated within 6 months of age; ET) HIV-infected children may represent a limitation or an advantage in the perspective of immune therapeutic studies.
2017
Authors: Colbers A, Schalkwijk S, Konopnicki D, Gingelmaier A, Lambert J, van der Ende I, Moltó J, Burger D.
Published: 24th Conference on Retroviruses and Opportunistic Infections, February 13th – 16th, 2017 – Seattle. Abstract number 754.
2017
Authors: Bernays S, Paparini S, Seeley J, Rhodes T.
Published in: Med Anthropol. 2017;36(5):485-499.
Abstract: Global health priorities are being set to address questions on adherence to HIV antiretroviral therapy in adolescence. Few studies have explored young people’s perspectives on the complex host of social and relational challenges they face in dealing with their treatment in secret and their condition in silence.
2017
Authors: Schomaker M, Leroy V, Wolfs T, et al. On behalf of theIeDEA West and Southern Africa regional collaborations and COHERE in EuroCoord.
Published in: Int J Epidemiol. 2017;46(2):453-465.
Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents.
Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients,
2017
Authors: Thorne C, Turkova A, Indolfi G, Venturini E, Giaquinto C
Published in: AIDS. 2017;31(1):127-135.
Objective To characterize children, adolescents and young adults infected with HIV/hepatitis C virus (HCV) vertically or before age of 18 years and living in Europe regarding mode of acquisition, HCV genotype, clinical status and treatment.
Design Retrospective,
2017
Authors:
Published in: Pediatr Infect Dis J.
2016
Authors: Colbers A, Best B, Schalkwijk S, et al. PANNA Network and the IMPAACT 1026 Study Team.
Published in: Clin Pharmacokinet. 2016;55(3):381-96
Abstract Pregnant women are usually excluded from clinical trials. Physiologically based pharmacokinetic (PBPK) modelling may provide a method to predict pharmacokinetics in pregnant women, without the need to perform extensive in vivo clinical trials.
2016
Authors: Bailey H, Malyuta R, Townsend C, Cortina Borja M, Thorne C for the Ukraine European Collaborative Study in EuroCoord.
Published in: Reprod Health. 2016;22(3):13-27.
Background Perinatal depression among HIV-positive women has negative implications for HIV-related and other maternal and infant outcomes. The aim of this study was to investigate the burden and correlates of perinatal depression among HIV-positive women in Ukraine,
2016
Authors: Turkova A, Chappell E, Chalermpantmetagul S, et al.
Published in: Int J Tuberc Lung Dis 2016;20(11):1448-1456.
Setting Centres participating in the Paediatric European Network for Treatment of AIDS (PENTA), including Thailand and Brazil.
Objective To describe the incidence, presentation, treatment and treatment outcomes of tuberculosis (TB) in human immunodeficiency virus (HIV) infected children.
2016
Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.
Published in: Antivir Ther. 2016; 21(4): 353-8
Background Surveillance for mid- and long-term antiretroviral therapy (ART) toxicity in children is important for informing treatment guidelines. We assessed the safety of darunavir (DRV) and atazanavir (ATV), commonly used as second-line protease inhibitors following lopinavir/ritonavir,
2016
Authors: Ngo-Giang-Huong N, Wittkop L, Judd A, et al. For EuroCoord-CHAIN-EPPICC joint project study group.
Published in: BMC Infect Dis. 2016;16(1):654.
Background Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
2016
Authors: Schalkwijk S, ter Heine R, Colbers A, Huitema A, Denti P, Dooley K, Capparelli E, Best B, Cressey T, Greupink R, Russel F, Mirochnick M, Burger D.
Published: 17th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, June 8th-10th 2016, Washington DC. P_26
2016
Authors: Colbers A, Schalkwijk S, Konopnicki D, Hawkins D, Hidalgo Tenorio C, Moltò J, Taylor G, Weizsacker K, van der Ende M, Burger D
Published: Oral presentation at 17th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, June 8th-10th 2016, Washington DC
2016
Authors: Schalkwijk S, Best B, Colbers A, SteK A, Wang J, Hawkins D, Mirochnick M, Burger D; for the The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1026s Protocol Team, and the Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-infected Pregnant Women (PANNA) Study Network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, February 22nd-25th 2016, Boston
2016
Authors: Blonk MI, Colbers AP, HidalgoTenorio C, et al.
Published in: Front Pharmacol. 2016 Aug 4;7:239.
Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women.
Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women.
2016
Authors: Schalkwijk S, Feiterna-Sperling C, Weizsacker K, et al.
Published in: AIDS. 2016; 30(12):1999-2001.
No Abstract available
2016
Author: Butler K, Inshaw J, Ford D, et al.
Published in: Health Technol Assess. 2016;20(49):1-108.
Background For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity, better adherence and cost savings.
Objectives To determine whether or not efavirenz (EFV)-based ART in short cycles of 5 days on and 2 days off is as efficacious (in maintaining virological suppression) as continuous EFV-based ART (continuous therapy;
2016
Author: The BREATHER (PENTA 16) Trial Group
Published in: Lancet HIV. 2016;3(9):e421-430
Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART).
2016
Authors: Schalkwijk S, Colbers A, Konopnicki D, et al. For PANNA network
Published in: AIDS. 2016;30(8):1239-44.
Objective To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum.
Design A nonrandomized, open-label, multicentre, phase-IV study.
Methods HIV-positive pregnant women receiving abacavir 600 mg q.d.
2016
Authors: Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C. Ukraine European Collaborative Study in EuroCoord.
Published in: BMC Pregnancy Childbirth. 2016;27;16:94
Background Over 3500 HIV-positive women give birth annually in Ukraine, a setting with high prevalence of sexually transmitted infections. Herpes simplex virus Type 2 (HSV-2) co-infection may increase HIV mother-to-child transmission (MTCT) risk.
2016
Authors: Ananworanich J, Melvin D, Ramos Amador JT, et al; on behalf of the PENTA 11 study group.
Published in: AIDS. 2016;30(7):1075-81.
Objective Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of life (QoL) are important for managing unplanned interruptions and planned interruptions in HIV cure research.
Design Children previously randomized to continuous (continuous ART,
2016
Authors: Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D; PANNA network.
Published in: AIDS. 2016;30(5):807-8.
Abstract not available
2016
Authors: Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.
Published in: Euro Surveill.2016;21(10): 30162
Abstract Accurate ascertainment of the number of children living with human immunodeficiency virus (HIV) is important to plan paediatric and adolescent health services. In Europe, the first generation of perinatally HIV-infected survivors are transferring to adult care and their health needs are unknown.
2016
Authors: S. Bernays, S. Paparini, D. Gibb & J. Seeley
Published in: Vulnerable Child Youth Stud. 2016;11(1):60-68
Abstract Despite mounting evidence recommending disclosure of human immunodeficiency virus (HIV) status to young people with perinatally acquired HIV as a central motivating factor for adherence to antiretroviral therapy, many young people continue to experience disclosure as a partial event,
2015
Authors: Moltò J, Valle M, Colbers A, Clotet V, Burger D.
Published: 16th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26th – 28th 2015, Westin Alexandria
2015
Authors: Harrison L, Melvin A, Fiscus S, et al. For PENPACT-1 (PENTA 9PACTG 390) Study Team.
Published in: JAIDS 2015;70(1):42-53
Background The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold.
Methods PENPACT-1 had a 2 × 2 factorial design,
2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T
Published: BSA Medical Sociology Conference, York, 9-11 September 2015 (Paper ID No: W0012148)
2015
Authors: Blonk MI, Colbers AP, Hidalgo-Tenorio C, et al. Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network; PANNA Network.
Published in: Clin Infect Dis. 2015; 61(5):809-816.
BackgroundThe use of raltegravir in human immunodeficiency virus (HIV)–infected pregnant women is important in the prevention of mother-to-child HIV transmission,
2015
Authors: Colbers A, Clotet V, Burger D.
Published: 16th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26th – 28th 2015, Westin Alexandria
2015
Authors: Best B, Colbers A, Wang J, Taylor G, Stek A, van Kasteren M, Mirochnick M, Burger D.
Published: 24th Conference on Retroviruses and Opportunistic Infections, March 23rd-26th 2015, Seattle. P_892
2015
Authors: Colbers A, Best B, Schalkwijk S, et al. PANNA Network and the IMPAACT 1026 Study Team.
Published in: Clin Infect Dis. 2015; 61(10):1582-1589.
Objective To describe the pharmacokinetics of maraviroc in human immunodeficiency virus (HIV)–infected women during pregnancy and post partum.
Methods HIV-infected pregnant women receiving maraviroc as part of clinical care had intensive steady-state 12-hour pharmacokinetic profiles performed during the third trimester and ≥2 weeks after delivery.
2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams.
Published in: accepted for presentation at AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435)
2015
Authors: Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team.
Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.
2015
Authors: Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S, Rhodes T and the BREATHER Trial Team.
Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.